Formerly dba Lexicon Genetics, Inc.. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. Only marginally SBIR-involved and that many years ago - and also preceding the firm going public - the company's lead candidates are LX4211 For the treatment of type 1 and 2 diabetes and LX1032/LX1606 for the treatement of carcinoid syndrome. LX4211 is an orally-delivered small molecule compound that inhibits both sodium-glucose cotransporter type 2, or SGLT2, a transporter responsible for most of the glucose reabsorption performed by the kidney, and sodium-glucose cotransporter type 1, or SGLT1, a transporter responsible for glucose and galactose absorption in the gastrointestinal tract. As of 2014 LX4211 was in phase II clinical trials. LX1032/LX1606 (Telotristat etiprate) is an orally-delivered small molecule compound that inhibits tryptophan hydroxylase, or TPH, the rate-limiting enzyme for serotonin production found primarily in enterochromaffin, or EC, cells of the gastrointestinal tract. Telotristat etiprate is, as of 2014, in phase III clinical trials.
